XML 50 R23.htm IDEA: XBRL DOCUMENT
v3.20.1

Disaggregation of Revenues (Tables) | 3 Months Ended
--- | ---
Mar. 31, 2020
Disaggregation of Revenue [Abstract] |
Disaggregation of Revenues | The following table disaggregates our product sales by product and geographic region and disaggregates our royalty, contract and other revenues by geographic region (in millions):
|  | Three Months Ended March 31, 2020 |  | Three Months Ended March 31, 2019
|  | U.S. |  | Europe |  | Other Locations |  | Total |  | U.S. |  | Europe |  | Other Locations |  | Total
Product sales: |  |  |  |  |  |  |  |  |  |  |  |  |  |  |  |
Atripla |  | $ | 81 |  |  | $ | 7 |  |  | $ | 7 |  |  | $ | 95 |  |  | $ | 133 |  |  | $ | 16 |  |  | $ | 22 |  |  | $ | 171 |
Biktarvy |  | 1,412 |  |  | 181 |  |  | 100 |  |  | 1,693 |  |  | 739 |  |  | 48 |  |  | 6 |  |  | 793 |
Complera/Eviplera |  | 24 |  |  | 47 |  |  | 5 |  |  | 76 |  |  | 44 |  |  | 62 |  |  | 9 |  |  | 115 |
Descovy |  | 363 |  |  | 61 |  |  | 34 |  |  | 458 |  |  | 233 |  |  | 68 |  |  | 41 |  |  | 342 |
Genvoya |  | 612 |  |  | 151 |  |  | 61 |  |  | 824 |  |  | 728 |  |  | 193 |  |  | 94 |  |  | 1,015 |
Odefsey |  | 269 |  |  | 127 |  |  | 13 |  |  | 409 |  |  | 282 |  |  | 106 |  |  | 9 |  |  | 397 |
Stribild |  | 34 |  |  | 17 |  |  | 2 |  |  | 53 |  |  | 67 |  |  | 18 |  |  | 11 |  |  | 96 |
Truvada |  | 383 |  |  | 8 |  |  | 15 |  |  | 406 |  |  | 551 |  |  | 33 |  |  | 22 |  |  | 606 |
Other HIV(1) |  | 3 |  |  | 2 |  |  | 3 |  |  | 8 |  |  | 11 |  |  | 1 |  |  | 5 |  |  | 17 |
Revenue share – Symtuza(2) |  | 72 |  |  | 38 |  |  | 2 |  |  | 112 |  |  | 42 |  |  | 24 |  |  | — |  |  | 66 |
AmBisome |  | 18 |  |  | 59 |  |  | 42 |  |  | 119 |  |  | 8 |  |  | 57 |  |  | 28 |  |  | 93 |
Ledipasvir/Sofosbuvir(3) |  | 53 |  |  | 11 |  |  | 48 |  |  | 112 |  |  | 117 |  |  | 27 |  |  | 81 |  |  | 225 |
Letairis |  | 83 |  |  | — |  |  | — |  |  | 83 |  |  | 197 |  |  | — |  |  | — |  |  | 197 |
Ranexa |  | 8 |  |  | — |  |  | — |  |  | 8 |  |  | 155 |  |  | — |  |  | — |  |  | 155 |
Sofosbuvir/Velpatasvir(4) |  | 311 |  |  | 122 |  |  | 131 |  |  | 564 |  |  | 230 |  |  | 154 |  |  | 107 |  |  | 491 |
Vemlidy |  | 73 |  |  | 7 |  |  | 56 |  |  | 136 |  |  | 65 |  |  | 4 |  |  | 32 |  |  | 101 |
Viread |  | 4 |  |  | 11 |  |  | 25 |  |  | 40 |  |  | 12 |  |  | 14 |  |  | 46 |  |  | 72 |
Vosevi |  | 33 |  |  | 11 |  |  | 4 |  |  | 48 |  |  | 45 |  |  | 16 |  |  | 2 |  |  | 63 |
Yescarta |  | 103 |  |  | 37 |  |  | — |  |  | 140 |  |  | 90 |  |  | 6 |  |  | — |  |  | 96 |
Zydelig |  | 8 |  |  | 12 |  |  | — |  |  | 20 |  |  | 11 |  |  | 15 |  |  | 1 |  |  | 27 |
Other(5) |  | 42 |  |  | 18 |  |  | 3 |  |  | 63 |  |  | 36 |  |  | 20 |  |  | 6 |  |  | 62 |
Total product sales |  | 3,989 |  |  | 927 |  |  | 551 |  |  | 5,467 |  |  | 3,796 |  |  | 882 |  |  | 522 |  |  | 5,200 |
Royalty, contract and other revenues |  | 17 |  |  | 48 |  |  | 16 |  |  | 81 |  |  | 22 |  |  | 56 |  |  | 3 |  |  | 81 |
Total revenues |  | $ | 4,006 |  |  | $ | 975 |  |  | $ | 567 |  |  | $ | 5,548 |  |  | $ | 3,818 |  |  | $ | 938 |  |  | $ | 525 |  |  | $ | 5,281 |
____________________
Notes:
(1) | Includes Emtriva and Tybost
(2) | Represents our revenue from cobicistat (C), emtricitabine (FTC) and tenofovir alafenamide (TAF) in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland UC
(3) | Amounts consist of sales of Harvoni and the authorized generic version of Harvoni sold by our separate subsidiary, Asegua Therapeutics LLC
(4) | Amounts consist of sales of Epclusa and the authorized generic version of Epclusa sold by our separate subsidiary, Asegua Therapeutics LLC
(5) | Includes Cayston, Hepsera and Sovaldi.

X
- References No definition available. + Details
Name: | us-gaap_DisaggregationOfRevenueAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration